Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 148

1.

Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 Pentetreotide.

Delpassand ES, Samarghandi A, Mourtada JS, Zamanian S, Espenan GD, Sharif R, Mackenzie S, Kosari K, Barakat O, Naqvi S, Seng JE, Anthony L.

Theranostics. 2012;2(5):472-80. doi: 10.7150/thno.3739. Epub 2012 May 11.

PMID:
22737186
[PubMed]
Free PMC Article
2.

The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria.

Zerizer I, Al-Nahhas A, Towey D, Tait P, Ariff B, Wasan H, Hatice G, Habib N, Barwick T.

Eur J Nucl Med Mol Imaging. 2012 Sep;39(9):1391-9. doi: 10.1007/s00259-012-2149-1. Epub 2012 May 30.

PMID:
22644713
[PubMed - indexed for MEDLINE]
3.

Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies.

Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE.

Semin Nucl Med. 2002 Apr;32(2):123-32.

PMID:
11965607
[PubMed - indexed for MEDLINE]
4.

Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.

Ezziddin S, Attassi M, Yong-Hing CJ, Ahmadzadehfar H, Willinek W, Grünwald F, Guhlke S, Biersack HJ, Sabet A.

J Nucl Med. 2014 Feb;55(2):183-90. doi: 10.2967/jnumed.113.125336. Epub 2014 Jan 16.

PMID:
24434296
[PubMed - indexed for MEDLINE]
5.

Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors.

Delpassand ES, Sims-Mourtada J, Saso H, Azhdarinia A, Ashoori F, Torabi F, Espenan G, Moore WH, Woltering E, Anthony L.

Cancer Biother Radiopharm. 2008 Jun;23(3):292-300. doi: 10.1089/cbr.2007.0448.

PMID:
18593362
[PubMed - indexed for MEDLINE]
6.

Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours.

Severi S, Nanni O, Bodei L, Sansovini M, Ianniello A, Nicoletti S, Scarpi E, Matteucci F, Gilardi L, Paganelli G.

Eur J Nucl Med Mol Imaging. 2013 Jun;40(6):881-8. doi: 10.1007/s00259-013-2369-z. Epub 2013 Feb 27.

PMID:
23443937
[PubMed - indexed for MEDLINE]
7.

Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients.

Versari A, Sollini M, Frasoldati A, Fraternali A, Filice A, Froio A, Asti M, Fioroni F, Cremonini N, Putzer D, Erba PA.

Thyroid. 2014 Apr;24(4):715-26. doi: 10.1089/thy.2013.0225. Epub 2013 Nov 14.

PMID:
24102584
[PubMed - in process]
8.

Long-term outcome and toxicity after dose-intensified treatment with 131I-MIBG for advanced metastatic carcinoid tumors.

Ezziddin S, Sabet A, Logvinski T, Alkawaldeh K, Yong-Hing CJ, Ahmadzadehfar H, Grünwald F, Biersack HJ.

J Nucl Med. 2013 Dec;54(12):2032-8. doi: 10.2967/jnumed.112.119313. Epub 2013 Oct 7.

PMID:
24101685
[PubMed - indexed for MEDLINE]
9.

Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors.

Buscombe JR, Caplin ME, Hilson AJ.

J Nucl Med. 2003 Jan;44(1):1-6.

PMID:
12515868
[PubMed - indexed for MEDLINE]
Free Article
10.

Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.

Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, Pu Y.

Acad Radiol. 2013 Jan;20(1):32-40. doi: 10.1016/j.acra.2012.07.002. Epub 2012 Sep 19.

PMID:
22999369
[PubMed - indexed for MEDLINE]
11.

Hepatic surgery for metastases from neuroendocrine tumors.

Sarmiento JM, Que FG.

Surg Oncol Clin N Am. 2003 Jan;12(1):231-42. Review.

PMID:
12735141
[PubMed - indexed for MEDLINE]
12.

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.

Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, Bartolomei M, Lombardo D, Ferrari ME, Sansovini M, Chinol M, Paganelli G.

Eur J Nucl Med Mol Imaging. 2011 Dec;38(12):2125-35. doi: 10.1007/s00259-011-1902-1. Epub 2011 Sep 3.

PMID:
21892623
[PubMed - indexed for MEDLINE]
13.

Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for unresectable primary and metastatic liver tumors.

Kucuk ON, Soydal C, Lacin S, Ozkan E, Bilgic S.

World J Surg Oncol. 2011 Aug 6;9:86. doi: 10.1186/1477-7819-9-86. Erratum in: World J Surg Oncol. 2011;9:120.

PMID:
21819613
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors.

Garin E, Le Jeune F, Devillers A, Cuggia M, de Lajarte-Thirouard AS, Bouriel C, Boucher E, Raoul JL.

J Nucl Med. 2009 Jun;50(6):858-64. doi: 10.2967/jnumed.108.057505. Epub 2009 May 14.

PMID:
19443590
[PubMed - indexed for MEDLINE]
Free Article
15.

68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.

Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D, Uprimny C, Kovacs P, Bale R, Virgolini IJ.

J Nucl Med. 2009 Sep;50(9):1427-34. doi: 10.2967/jnumed.108.053421. Epub 2009 Aug 18.

PMID:
19690033
[PubMed - indexed for MEDLINE]
Free Article
16.

[Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker].

Pfannenberg AC, Oechsle K, Kollmannsberger C, Dohmen BM, Bokemeyer C, Bares R, Vontheim R, Claussen CD.

Rofo. 2004 Jan;176(1):76-84. German.

PMID:
14712410
[PubMed - indexed for MEDLINE]
17.

68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors.

Haug AR, Auernhammer CJ, Wängler B, Schmidt GP, Uebleis C, Göke B, Cumming P, Bartenstein P, Tiling R, Hacker M.

J Nucl Med. 2010 Sep;51(9):1349-56. doi: 10.2967/jnumed.110.075002. Epub 2010 Aug 18.

PMID:
20720050
[PubMed - indexed for MEDLINE]
Free Article
18.

The prognostic value of 18F-FDG PET-CT in the management of Hodgkin's lymphoma: preliminary results of a prospective study.

Paolini R, Rampin L, Rodella E, Ramazzina E, Banti E, Al-Nahhas A, Rubello D.

Nucl Med Rev Cent East Eur. 2007;10(2):87-90.

PMID:
18228212
[PubMed - indexed for MEDLINE]
19.

PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST).

Ding Q, Cheng X, Yang L, Zhang Q, Chen J, Li T, Shi H.

J Thorac Dis. 2014 Jun;6(6):677-83. doi: 10.3978/j.issn.2072-1439.2014.05.10.

PMID:
24976990
[PubMed]
Free PMC Article
20.

Metabolic and receptor imaging in patients with neuroendocrine tumors: comparison of fludeoxyglucose-positron emission tomography and computed tomography with indium in 111 pentetreotide.

Zalom ML, Waxman AD, Yu R, Lee J, Ih G, Wolin EM.

Endocr Pract. 2009 Sep-Oct;15(6):521-7. doi: 10.4158/EP08318.ORR1.

PMID:
19491080
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk